Breast Cancer News
In this section, access cutting-edge news about breast cancer in young women including treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
After evaluating long-term results from recent studies, the American Society of Clinical Oncology, ASCO, issued a guideline update for tamoxifen therapy for hormone receptor-positive breast cancer.
The update advises doctors to offer up to 10 years of tamoxifen treatment, instead of the previous standard 5-year duration
LBBC highlights results of a phase III clinical trial studying a medicine used to protect premenopausal women’s ovaries during chemotherapy. Findings were announced during the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.
LBBC highlights a study reported on the first day of the American Society of Clinical Oncology 2014 Breast Cancer Symposium: an analysis of breast cancer recurrence rates after pre-surgery, or neoadjuvant, chemotherapy.
Although more women are having lumpectomies, an evaluation of data in the National Cancer Database found socioeconomic barriers prevent some from choosing this surgery. Meeghan Ann Lautner, MD, of the University of Texas San Antonio, announced findings at the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.
Two recent studies found that those diagnosed with breast cancer at younger ages are more likely to experience difficulties with certain symptoms and side effects than those diagnosed when older.
Life expectancy improves only slightly for women with cancer in one breast who choose to remove the healthy breast along with the affected one, a recent study shows.
Treating hormone receptor-positive breast cancer with an aromatase inhibitor, or AI, usually used only in postmenopausal women, significantly reduced breast cancer return in premenopausal women when used with ovarian suppression , according to the preliminary reports of two combined studies.
Most young women diagnosed with early-stage breast cancer are at risk of becoming infertile from treatment, according to a study from the Centers for Disease Control and Prevention (CDC) and other researchers.
Before and during chemotherapy, giving premenopausal women with estrogen receptor-negative (ER-) breast cancer the medicine goserelin (Zoladex) improved their ability to become pregnant several years after treatment and to deliver healthy babies.
Sunday reports from the 50th annual meeting of the American Society of Clinical Oncology focused on using aromatase inhibitors in premenopausal women with early-stage, estrogen-positive breast cancer and on a negative study of lapatinib for HER2-positive early-stage disease.